$7.69 -0.06 (-0.77%)
11/6/2009 4:01 PM

Simcere Pharmaceutical Group (SCR)

CAPS Rating: 5 out of 5

The Company is a manufacturer and supplier of branded generic pharmaceuticals in the fast growing China market.

Current Price $7.69 Mkt Cap $481.19M
Open $7.64 P/E Ratio 9.45
Prev. Close $7.75 Div. (Yield) N/A (N/A)
Daily Range $7.63 - $7.79 Volume 51,625
52-Wk Range $4.76 - $9.98 Avg. Daily Vol. 81,000

SCR News and Commentary

Caps

How do you think SCR will perform vs the S&P 500?

Add Stock to Watchlist

All Members

252 Outperform
6 Underperform
 

All-Star Members

88 Outperform
1 Underperform
 

Wall Street

3 Outperform
1 Underperform
 

Top SCR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mrindependent (98.79)
Submitted August 25, 2009

Simcere Pharmaceutical is a rapidly growing generic pharmaceuticals company located in China. The company has tripled its revenues in the last 5 years and seems poised for future growth. Price has dropped recently due to combination of a China stock… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

SCR VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about SCR.

Recs

0
Member Avatar jemsa (84.96) Submitted: 9/18/2009 1:43:11 PM : Outperform Start Price: $7.99 SCR Score: -3.87

This Chinese branded pharmaceutical maker seems dramatically underpriced (see pitch by Mr Independent). The stock has performed poorly recently but I think chinese small caps and healthcare stocks will get hot soon. Following BullishBabo

Recs

0
Member Avatar spundun (68.07) Submitted: 8/26/2009 2:04:40 PM : Outperform Start Price: $7.56 SCR Score: -2.60

HT mrindependent
I support generic drug companies.

Recs

3
Member Avatar mrindependent (98.79) Submitted: 8/25/2009 1:53:11 PM : Outperform Start Price: $7.56 SCR Score: -2.54

Simcere Pharmaceutical is a rapidly growing generic pharmaceuticals company located in China. The company has tripled its revenues in the last 5 years and seems poised for future growth. Price has dropped recently due to combination of a China stock market pullback and a recent earnings miss. As a result, this extremely attractive company is available for just 1.44 times book value and 15 times estimated 2009 earnings. The balance sheet is sold with approximately $0.70 per share in net cash.

Leaderboard

Find the members with the highest scoring picks in SCR.

Score Leader

ChrisGraley

ChrisGraley (99.67) Score: +67.01

Reloading after the earnings drop.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
Xucolat 60.26 10/29/2008 Outperform 5Y $4.92 +56.30% +17.76% +38.54 1 Comment
12371 96.55 11/2/2007 Underperform NS $15.99 -51.91% -25.93% +25.98
snazzysnazz 40.99 3/19/2009 Outperform 5Y $4.83 +59.21% +34.65% +24.57
ebarrett4 91.81 11/3/2008 Outperform 5Y $5.69 +35.15% +13.45% +21.70 1 Comment
Top20Tracker 87.54 11/3/2008 Outperform NS $5.69 +35.15% +13.45% +21.70
Supernanny543 46.95 8/5/2008 Underperform 3W $11.49 -33.07% -12.30% +20.77
HarryFuzzball 98.37 3/23/2009 Outperform 1Y $4.99 +54.11% +37.48% +16.63
saaf569 98.25 3/25/2009 Outperform 3Y $5.17 +48.74% +33.11% +15.63
hwyman64 96.18 3/25/2009 Outperform 5Y $5.17 +48.74% +33.11% +15.63
pops83 55.28 4/9/2008 5/24/2009 Underperform 3M $11.50 -33.13% -18.68% +14.45

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSusquehanna 74.76 10/20/2009 Outperform NS $8.01 -4.00% -2.56% -1.43
TrackPiperJaff 80.38 5/5/2009 Outperform NS $7.80 -2.05% +17.23% -19.28 9/25/2009 @ $7.64
TrackBreanMurray 89.84 12/10/2008 Outperform NS $6.81 +12.92% +21.66% -8.74
TrackRothCapital 75.81 8/22/2008 Outperform NS $12.52 -38.58% -14.09% -24.49
TrackJimCramer < 20 4/23/2007 Underperform 3W $17.50 -56.06% -23.51% +32.55

Featured Broker Partners